Literature DB >> 22742658

QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability.

Fabio Broccatelli1, Raimund Mannhold, Alessio Moriconi, Sandra Giuli, Emanuele Carosati.   

Abstract

We collected 1173 hERG patch clamp (PC) data (IC50) from the literature to derive twelve classification models for hERG inhibition, covering a large variety of chemical descriptors and classification algorithms. Models were generated using 545 molecules and validated through 258 external molecules tested in PC experiments. We also evaluated the suitability of the best models to predict the activity of 26 proprietary compounds tested in radioligand binding displacement (RBD). Results proved the necessity to use multiple validation sets for a true estimation of model accuracy and demonstrated that using various descriptors and algorithms improves the performance of ligand-based models. Intriguingly, one of the most accurate models uncovered an unexpected link between extent of metabolism and hERG liability. This hypothesis was fairly reinforced by using the Biopharmaceutics Drug Disposition Classification System (BDDCS) that recognized 94% of the hERG inhibitors as extensively metabolized in vivo. Data mining suggested that high Torsades de Pointes (TdP) risk results from an interplay of hERG inhibition, extent of metabolism, active transport, and possibly solubility. Overall, these new findings might improve both the decision making skills of pharmaceutical scientists to mitigate hERG liability during the drug discovery process and the TdP risk assessment during drug development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22742658     DOI: 10.1021/mp300156r

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  9 in total

Review 1.  BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Authors:  Chelsea M Hosey; Rosa Chan; Leslie Z Benet
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

2.  Compilation and physicochemical classification analysis of a diverse hERG inhibition database.

Authors:  Remigijus Didziapetris; Kiril Lanevskij
Journal:  J Comput Aided Mol Des       Date:  2016-10-25       Impact factor: 3.686

3.  Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity.

Authors:  Chuipu Cai; Pengfei Guo; Yadi Zhou; Jingwei Zhou; Qi Wang; Fengxue Zhang; Jiansong Fang; Feixiong Cheng
Journal:  J Chem Inf Model       Date:  2019-02-15       Impact factor: 4.956

4.  Tuning HERG out: antitarget QSAR models for drug development.

Authors:  Rodolpho C Braga; Vinicius M Alves; Meryck F B Silva; Eugene Muratov; Denis Fourches; Alexander Tropsha; Carolina H Andrade
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

Review 6.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

7.  Fusing dual-event data sets for Mycobacterium tuberculosis machine learning models and their evaluation.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2013-10-30       Impact factor: 4.956

8.  Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors.

Authors:  Joseph J Babcock; Fang Du; Kaiping Xu; Sarah J Wheelan; Min Li
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Capsule Networks Showed Excellent Performance in the Classification of hERG Blockers/Nonblockers.

Authors:  Yiwei Wang; Lei Huang; Siwen Jiang; Yifei Wang; Jun Zou; Hongguang Fu; Shengyong Yang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.